Valeant Slumps as New CEO Faulted by Successor at PerrigoBy and
Perrigo’s new CEO calls recent track record ‘unacceptable’
Papa hired to improve Valeant’s fortunes after missteps
Shares of Valeant Pharmaceuticals International Inc. fell 5.4 percent after the past performance of its new chief executive officer, Joseph Papa, was criticized by the CEO who succeeded him at his previous company.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.